HRP20190184T1 - Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1 - Google Patents

Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1

Info

Publication number
HRP20190184T1
HRP20190184T1 HRP20190184TT HRP20190184T HRP20190184T1 HR P20190184 T1 HRP20190184 T1 HR P20190184T1 HR P20190184T T HRP20190184T T HR P20190184TT HR P20190184 T HRP20190184 T HR P20190184T HR P20190184 T1 HRP20190184 T1 HR P20190184T1
Authority
HR
Croatia
Prior art keywords
esterase
cleared
organism
inhibitor
discussion
Prior art date
Application number
HRP20190184TT
Other languages
English (en)
Croatian (hr)
Inventor
Colin Broom
Marc E. Uknis
Original Assignee
Shire Viropharma Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190184(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Incorporated filed Critical Shire Viropharma Incorporated
Publication of HRP20190184T1 publication Critical patent/HRP20190184T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20190184TT 2013-11-22 2014-11-21 Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1 HRP20190184T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US201462029086P 2014-07-25 2014-07-25
PCT/US2014/066784 WO2015077543A1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
EP14809567.2A EP3071219B1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Publications (1)

Publication Number Publication Date
HRP20190184T1 true HRP20190184T1 (hr) 2019-03-22

Family

ID=52016153

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190184TT HRP20190184T1 (hr) 2013-11-22 2014-11-21 Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1

Country Status (24)

Country Link
US (3) US9895428B2 (https=)
EP (3) EP4162947A1 (https=)
JP (5) JP6431912B2 (https=)
KR (2) KR102312817B1 (https=)
CN (2) CN111388655A (https=)
AU (2) AU2014352846B2 (https=)
BR (1) BR112016011499A2 (https=)
CA (1) CA2930964A1 (https=)
CY (1) CY1121298T1 (https=)
DK (1) DK3071219T3 (https=)
ES (1) ES2708655T3 (https=)
HR (1) HRP20190184T1 (https=)
HU (1) HUE041809T2 (https=)
LT (1) LT3071219T (https=)
ME (1) ME03318B (https=)
MX (2) MX378834B (https=)
NZ (2) NZ719724A (https=)
PL (1) PL3071219T3 (https=)
PT (1) PT3071219T (https=)
RS (1) RS58343B1 (https=)
SG (1) SG10201804326SA (https=)
SI (1) SI3071219T1 (https=)
SM (1) SMT201900042T1 (https=)
WO (1) WO2015077543A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
CA3075686A1 (en) * 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
US20220073605A1 (en) * 2018-12-20 2022-03-10 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
AU2020327043A1 (en) * 2019-08-08 2022-02-24 Cedars-Sinai Medical Center Methods of improving organ function
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
AU2021381360A1 (en) * 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
WO2024152030A1 (en) * 2023-01-13 2024-07-18 The Uab Research Foundation Crossmatching for porcine xenotransplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
RS53864B1 (sr) * 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa
DK2758076T3 (en) * 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
CA2901225C (en) * 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
BR112015023207A8 (pt) * 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Also Published As

Publication number Publication date
EP3071219B1 (en) 2018-11-14
CA2930964A1 (en) 2015-05-28
JP6620206B2 (ja) 2019-12-11
BR112016011499A2 (pt) 2020-10-27
AU2014352846A1 (en) 2016-06-02
SI3071219T1 (sl) 2019-03-29
JP2022179637A (ja) 2022-12-02
RS58343B1 (sr) 2019-03-29
MX2016006656A (es) 2016-09-06
JP2016537380A (ja) 2016-12-01
HUE041809T2 (hu) 2019-05-28
KR20160079821A (ko) 2016-07-06
JP2019023233A (ja) 2019-02-14
KR102312817B1 (ko) 2021-10-13
CN105744949A (zh) 2016-07-06
US20150147319A1 (en) 2015-05-28
JP2021063141A (ja) 2021-04-22
ME03318B (me) 2019-10-20
KR20210125118A (ko) 2021-10-15
CN111388655A (zh) 2020-07-10
MX378834B (es) 2025-03-11
PT3071219T (pt) 2019-02-06
KR102384814B1 (ko) 2022-04-08
MX2021000332A (es) 2021-04-13
EP4162947A1 (en) 2023-04-12
AU2014352846B2 (en) 2019-10-03
LT3071219T (lt) 2019-01-10
WO2015077543A1 (en) 2015-05-28
JP2019001831A (ja) 2019-01-10
SG10201804326SA (en) 2018-06-28
NZ719724A (en) 2022-08-26
US20180104319A1 (en) 2018-04-19
DK3071219T3 (en) 2019-02-25
EP3494988A1 (en) 2019-06-12
CY1121298T1 (el) 2020-05-29
ES2708655T3 (es) 2019-04-10
JP6431912B2 (ja) 2018-11-28
EP3494988B1 (en) 2022-08-03
NZ759187A (en) 2022-08-26
PL3071219T3 (pl) 2019-04-30
US20200360495A1 (en) 2020-11-19
AU2020200015B2 (en) 2022-03-10
AU2020200015A1 (en) 2020-01-30
SMT201900042T1 (it) 2019-02-28
EP3071219A1 (en) 2016-09-28
US9895428B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
HRP20190184T1 (hr) Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1
IL243976A0 (en) kdm1a inhibitors for disease treatment
PL4374873T3 (pl) Środek do stosowania w leczeniu lub zapobieganiu schorzeniom okulistycznym
IL235055A0 (en) Patient matching surgical guide and method for using the same
IL246141A0 (en) Methods for adhering tissue surfaces and materials and biomedical uses thereof
EP2962268A4 (en) SYSTEMS AND METHODS FOR ENHANCING CLINICAL DOCUMENTATION
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
EP2968894A4 (en) MEDICAL CONNECTOR
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
IL243481A0 (en) Drug for treatment of nonalcoholic fatty liver disease
HRP20181378T1 (hr) Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom
DK2764881T3 (da) System til medicinsk behandling
IL234606B (en) Novel methods and composition for treatment of disease
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
EP2839068A4 (en) Clothes treatment apparatus
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
EP2994184C0 (en) An unravelable catheter
GB201309375D0 (en) Medical methods and compounds for medical use
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
DK2976101T3 (da) Behandlingsfremgangsmåde
EP2982310A4 (en) Medical manipulator
DK3041506T3 (da) Behandlingsfremgangsmåde